Yahoo
Shanghai - Delayed Quote CNY

Xiamen Amoytop Biotech Co., Ltd. (688278.SS)

43.80 -0.42 (-0.95%)
At close: 3:00:01 PM GMT+8
Chart Range Bar
Loading chart for 688278.SS
  • Previous Close 44.22
  • Open 44.14
  • Bid 43.77 x --
  • Ask 43.80 x --
  • Day's Range 42.35 - 45.00
  • 52 Week Range 41.11 - 85.57
  • Volume 3,069,199
  • Avg. Volume 3,706,220
  • Market Cap (intraday) 17.879B
  • Beta (5Y Monthly) -0.14
  • PE Ratio (TTM) 21.37
  • EPS (TTM) 2.05
  • Earnings Date --
  • Forward Dividend & Yield 0.62 (1.40%)
  • Ex-Dividend Date May 29, 2026
  • 1y Target Est 80.00

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

www.amoytop.com

3,644

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688278.SS
47.07%
SSE Composite Index (000001.SS)
8.00%

1-Year Return

688278.SS
38.39%
SSE Composite Index (000001.SS)
9.09%

3-Year Return

688278.SS
4.24%
SSE Composite Index (000001.SS)
21.00%

5-Year Return

688278.SS
65.75%
SSE Composite Index (000001.SS)
2.93%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 895.81M
Earnings --
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
200M
400M
600M
800M
1B
1B
0.0%

Analyst Insights

View More

Analyst Price Targets

80.00
80.00 Average
43.80 Current
80.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.34%

  • Return on Assets (ttm)

    13.31%

  • Return on Equity (ttm)

    26.98%

  • Revenue (ttm)

    3.95B

  • Net Income Avi to Common (ttm)

    842.48M

  • Diluted EPS (ttm)

    2.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.24B

  • Total Debt/Equity (mrq)

    67.97%

  • Levered Free Cash Flow (ttm)

    -45.92M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: